BRAK Mouse

CXCL14 is structurally related to other members of the CXC chemokine family but lacks the ELR domain preceding the CXC motif, which is present in some other CXC chemokines . The protein is constitutively expressed at high levels in various normal tissues, including the basal layer of epidermal keratinocytes, dermal fibroblasts, and lamina propria cells in the intestines .

CXCL14 displays chemotactic activity specifically for monocytes but not for lymphocytes, dendritic cells, neutrophils, or macrophages . This selective chemotactic activity suggests that CXCL14 plays a role in the homeostasis of monocyte-derived macrophages rather than in inflammatory responses . Additionally, CXCL14 has been implicated in tumor suppression and fat metabolism modulation, making it a potential therapeutic candidate for related diseases .

Recombinant mouse CXCL14/BRAK is typically produced in E. coli expression systems. The recombinant protein is purified using proprietary chromatographic techniques to achieve high purity levels, often exceeding 97-98% as determined by SDS-PAGE and HPLC analyses . The endotoxin levels are kept very low, usually below 0.01 EU per 1 μg of protein .

Recombinant CXCL14/BRAK is used in various research applications, including studies on chemotaxis, immunoregulation, and inflammation. It is also utilized in functional assays to investigate its role in monocyte chemoattraction and its potential therapeutic applications in cancer and metabolic diseases .

The recombinant protein is supplied as a lyophilized powder or in a solution, and it is recommended to store it at -20°C to -70°C to maintain its stability. Repeated freeze-thaw cycles should be avoided to preserve its activity .